DKK1395m market cap
DKK5.21 last close
BioPorto Diagnostics is a diagnostic company focused on the development and commercialisation of biomarker-based assays. The company’s portfolio includes The NGAL Test, for the prediction of acute kidney injury, and an extensive antibody library.
Investment summary
BioPorto managed to continue sales growth for its NGAL research-use only (RUO) product in 2020 despite the headwinds of COVID-19. Sales of the product increased 28% over the prior year (DKK13.4m from DKK10.5m) despite the disruption. We are encouraged to see this growth as we expect physicians with exposure to the test to become the first customers after the launch of the approved NGAL Test for clinical use.
Y/E Dec |
Revenue (DKKm) |
EBITDA (DKKm) |
PBT (DKKm) |
EPS (ore) |
P/E (x) |
P/CF (x) |
---|---|---|---|---|---|---|
2019A | 26.6 | (68.3) | (71.1) | (39.16) | N/A | N/A |
2020A | 23.2 | (54.3) | (61.5) | (28.10) | N/A | N/A |
2021E | 32.2 | (71.4) | (74.9) | (25.33) | N/A | N/A |
2022E | 179.3 | 68.3 | 64.5 | 20.79 | 25.1 | N/A |
Industry outlook
The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.
Last updated on 13/04/2021
Sector |
---|
Healthcare |
Share price graph
Balance sheet |
|
---|---|
Forecast net cash (DKKm) | 46.4 |
Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |
Key management |
|
---|---|
Thomas Magnussen | Chairman |
Peter Mørch Eriksen | CEO |
Ole Larsen | CFO |
Jan Kuhlmann Andersen | COO |
You may also be interested in…
- 4SC
- Abliva
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- ASIT biotech
- Basilea Pharmaceutica
- BerGenBio
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nicox
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma